StuartHIsaacsonMDFAAN

Neurology • Boca Raton, FL

Movement Disorder

Director and Founder Parkinson's Disease and Movement Disorders Center of Boca Raton

Join to view full profile

Dr. Isaacson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Isaacson's full profile

Already have an account?

Office
Parkinson’s Disease and Movement Disorders Center of Boca Raton
951 Nw 13th St, Bldg 5-E
Boca Raton, FL 33486
Phone+1 561-392-1818

Fax+1 561-392-8989

Summary

Stuart H. Isaacson, MD, FAAN is the Director of the Parkinson’s Disease and Movement Disorders Center of Boca Raton in Florida. Dr. Isaacson has been involved in over 250 clinical trials, and has served as Principal Investigator and on steering committees for many therapeutic development programs, and has authored or co-authored over 200 journal articles, abstracts, and book chapters.

Education & Training

Icahn School of Medicine at Mount SinaiFellowship, Neuromuscular Medicine (Neurology), 1995 - 1996
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Neurology, 1989 - 1992
Icahn School of Medicine at Mount Sinai/Morningside/WestInternship, Internal Medicine, 1988 - 1989
Northwestern University The Feinberg School of MedicineClass of 1988

Certifications & Licensure

FL State Medical License 1997 - 2026
NY State Medical License 1989 - 2025
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014-2024
Super Doctor SuperDoctors.com

Clinical Trials

Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression Start of enrollment: 2010 Jun 01
Completed
Phase 2
A Post Marketing Observational Study of Activities of Daily Living in Advanced Parkinson's Disease Patients With Early Troublesome Motor Fluctuations and Treated With Duodopa - a Multi-country Study Start of enrollment: 2013 Feb 01
Completed
Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT) Start of enrollment: 2012 Dec 01
Completed
Phase 4
A Study to Examine APL-130277 in Patients With Parkinson's Disease Start of enrollment: 2014 Aug 31
Completed
Phase 2
Evaluation of Safety and Tolerability of ENT-01 for the Treatment of Parkinson's Disease Related Constipation Start of enrollment: 2017 May 11
Completed
Phase 1, Phase 2
The Effect of Parkinson Kinetigraph Recordings on the Management and Outcome in Parkinson's Disease Start of enrollment: 2017 Apr 30
Completed
Not Applicable
A Phase 3 Study With P2B001 in Subjects With Early Parkinson's Start of enrollment: 2018 Jan 19
Completed
Phase 3
Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide) Start of enrollment: 2017 Nov 30
Completed
Fixed-Dose Trial in Early Parkinson's Disease (PD) Start of enrollment: 2019 Dec 13
COMPLETED
PHASE3
Roles: Contact
Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations Start of enrollment: 2020 Oct 27
COMPLETED
PHASE3
Open-label Trial in Parkinson's Disease (PD) Start of enrollment: 2021 Feb 24
Enrolling by invitation
Phase 3
Roles: Contact
A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004 Start of enrollment: 2016 Jul 01
Unknown status
Phase 3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Continuous, subcutaneous apomorphine infusion for Parkinson disease motor fluctuations: Results from the phase 3, long-term, open-label United States InfusON study.
Stuart H Isaacson, Alberto J Espay, Rajesh Pahwa, Pinky Agarwal, Holly A Shill
Journal of Parkinson's Disease. 2025-01-29
Moving to a non-dopaminergic approach for the treatment of OFF fluctuations in Parkinson's disease.
Stuart H Isaacson, Peter Jenner
Clinical Parkinsonism & Related Disorders. 2025-01-01
Hope vs. Hype III: Rescue/on-demand therapies are preferable to device-assisted therapies in Parkinson disease.
Stuart Isaacson, Oliver Phillips, Joohi Jimenez-Shahed
Parkinsonism & Related Disorders. 2024-09-01

Press Mentions

Supernus Announces FDA Approval of ONAPGO™ (Apomorphine Hydrochloride) for Parkinson’s DiseaseFebruary 4th, 2025
BeyoND Phase 2b Data Indicates ND0612 Has a Positive Long-Term Safety Profile for People with Parkinson's DiseaseApril 4th, 2022
Cala Health Receives FDA Breakthrough Device Designation for Cala Trio™ Therapy to Treat Action Tremors in Parkinson's DiseaseOctober 22nd, 2020
Join now to see all